Key result
Growth hormone therapy in children with idiopathic GH deficiency faces unresolved diagnostic challenges, including poor reproducibility of stimulation tests and arbitrary threshold definitions.
Why the study?
Major clinical problems regarding arbitrary diagnostic thresholds, test inaccuracy, and optimal duration of GH therapy in children with isolated GHD have remained unresolved for decades.
This review highlights the need to resolve long-standing diagnostic and therapeutic challenges in managing children with idiopathic growth hormone deficiency to optimize their care.
Answers are grounded in this paper and cite their sources.
Diagnostic inconsistencies in idiopathic GH deficiency warrant cautious therapy decisions; leaves open standardization of stimulation thresholds.
According to current guidelines, growth hormone (GH) therapy is strongly recommended in children and adolescents with GH deficiency (GHD) in order to accelerate growth rate and attain normal adult height. The diagnosis of GHD requires demonstration of decreased GH secretion in stimulation tests, below the established threshold value. Currently, GHD in children is classified as secondary insulin-like growth factor-1 (IGF-1) deficiency. Most of children diagnosed with isolated GHD presents with normal GH secretion at the attainment of near-final height or even in mid-puberty. The most important clinical problems, related to the diagnosis of isolated GHD in children and to optimal duration of rhGH therapy include: arbitrary definition of subnormal GH peak in stimulation tests, disregarding factors influencing GH secretion, insufficient diagnostic accuracy and poor reproducibility of GH stimulation tests, discrepancies between spontaneous and stimulated GH secretion, clinical entity of neurosecretory dysfunction, discrepancies between IGF-1 concentrations and results of GH stimulation tests, significance of IGF-1 deficiency for the diagnosis of GHD, a need for validation IGF-1 reference ranges. Many of these issues have remained unresolved for 25 years or even longer. It seems that finding solutions to them should optimize diagnostics and therapy of children with short stature.
No takes yet. Share an insight, caveat, or question.
Joanna Smyczyńska (2022) conducted a review in Idiopathic Growth Hormone Deficiency. Growth Hormone (GH) Therapy was evaluated. Growth hormone therapy in children with idiopathic GH deficiency faces unresolved diagnostic challenges, including poor reproducibility of stimulation tests and arbitrary threshold definitions.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: